News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cornerstone Therapeutics Inc. Announces Initiation of Phase 2 Clinical Trial of CPI-613 for the Treatment of Small Cell Lung Cancer


10/24/2013 9:40:12 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a pilot Phase II clinical trial of CPI-613 for the treatment of relapsed or refractory small cell lung cancer (SCLC) patients. CPI-613 is the company's lead Altered Energy Metabolism Directed (AEMD) drug candidate, which is designed to disrupt the altered energy-production pathways in cancer cells.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES